PSMA-targeted theranostic nanoplex for prostate cancer therapy. - Wikidata - wikimedia - TriplyDB

PSMA-targeted theranostic nanoplex for prostate cancer therapy.

PSMA-targeted theranostic nanoplex for prostate cancer therapy.

http://www.wikidata.org/entity/Q33791366

about

Therapeutic efficacy of nanomedicines for prostate cancer: An update Prostate-specific membrane antigen as a target for cancer imaging and therapy Targeted nanotechnology for cancer imaging.Theranostic nanoparticles Molecular imaging of the tumor microenvironment for precision medicine and theranostics.NIH workshop on clinical translation of molecular imaging probes and technology--meeting report.In-fiber production of polymeric particles for biosensing and encapsulation.Oxcarbazepine-loaded polymeric nanoparticles: development and permeability studies across in vitro models of the blood-brain barrier and human placental trophoblast.Comparative analysis of monoclonal antibodies against prostate-specific membrane antigen (PSMA).Targeting prostate cancer cells with PSMA inhibitor-guided gold nanoparticles.Dendrimer nanoscaffolds for potential theranostics of prostate cancer with a focus on radiochemistry.Magnetic Resonance Spectroscopy of siRNA-Based Cancer Therapy Preclinical evaluation of 86Y-labeled inhibitors of prostate-specific membrane antigen for dosimetry estimates Dimeric DNA Aptamer Complexes for High-capacity-targeted Drug Delivery Using pH-sensitive Covalent Linkages Degradable Dextran Nanopolymer as a Carrier for Choline Kinase (ChoK) siRNA Cancer Therapy.Ultrahigh affinity Raman probe for targeted live cell imaging of prostate cancer Recent advances in delivery of drug-nucleic acid combinations for cancer treatment Molecular imaging of prostate cancer: translating molecular biology approaches into the clinical realm.Next revolution in molecular theranostics: personalized medicine for urologic cancers.⁶⁴Cu-labeled inhibitors of prostate-specific membrane antigen for PET imaging of prostate cancer.MiR-143 Targeting TAK1 Attenuates Pancreatic Ductal Adenocarcinoma Progression via MAPK and NF-κB Pathway In Vitro.Specific Delivery of MiRNA for High Efficient Inhibition of Prostate Cancer by RNA Nanotechnology.PSMA-specific theranostic nanoplex for combination of TRAIL gene and 5-FC prodrug therapy of prostate cancer.Oligonucleotide-based theranostic nanoparticles in cancer therapy.The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease Synthesis and Evaluation of Gd(III) -Based Magnetic Resonance Contrast Agents for Molecular Imaging of Prostate-Specific Membrane Antigen Furin-mediated sequential delivery of anticancer cytokine and small-molecule drug shuttled by graphene.Magnetic Resonance Imaging and Spectroscopy in Cancer Theranostic Imaging.LHRH-conjugated micelles for targeted delivery of antiandrogen to treat advanced prostate cancer.111In- and IRDye800CW-Labeled PLA-PEG Nanoparticle for Imaging Prostate-Specific Membrane Antigen-Expressing Tissues.Mechanism of three-component collision to produce ultrastable pRNA three-way junction of Phi29 DNA-packaging motor by kinetic assessment.Mouse glutamate carboxypeptidase II (GCPII) has a similar enzyme activity and inhibition profile but a different tissue distribution to human GCPII.Development and Application of a Novel Model System to Study "Active" and "Passive" Tumor Targeting.Acid-degradable Dextran as an Image Guided siRNA Carrier for COX-2 Downregulation.Guidelines for Rational Cancer Therapeutics.Radionuclides in oncology clinical practice - review of the literature.Towards matched pairs of porphyrin-Re(I) /(99m) Tc(I) conjugates that combine photodynamic activity with fluorescence and radio imaging.Detection and quantitation of glutamate carboxypeptidase II in human blood.Gel-Liposome-Mediated Co-Delivery of Anticancer Membrane-Associated Proteins and Small-Molecule Drugs for Enhanced Therapeutic Efficacy

P2860

Q26766305-E0CF8DE0-8A42-455F-AA6C-899D7C544762 Q26799439-F2C13DDC-17AE-4675-A4A5-DFC13935F63C Q27010317-ACEA69AD-9438-44E4-B93F-99628FB5E1EC Q28650348-29EC40B8-A5D0-4CCC-8819-9442F23DFB8D Q30367515-80A0AE7B-39F3-47F0-B8C0-93B594FA1DC2 Q30430958-03110F73-A809-442C-8125-72EAD1852C36 Q34982558-165656B1-79B9-4522-9AE2-1C7C36211D66 Q35185771-93C73092-C84F-48A0-AF80-9CF97D498357 Q35282416-79D1CDB4-E56B-4CC2-9DC3-B01BEF55AA08 Q36501550-2C138C1C-9EBA-4897-8B0F-EC23FD8284D9 Q36690711-DE12B186-3D18-47DB-B867-D9A027DDCB0C Q36910668-025C5E01-28A4-4099-B2AC-E8FE35BAE88F Q36928870-7766CDA5-3DBC-422A-BAA5-EDC4D8CF0936 Q37065549-029BE342-70D5-41E6-B338-181E55F61923 Q37636194-DEF1A483-B168-4F12-9923-4CBB56EBE0EF Q37708073-481A9DFB-2F33-45CF-B304-07565CAA6740 Q38102522-C57012F4-98B0-4A6A-BF3D-60EEE73D9D5A Q38360681-D8EB81F8-8CCB-427B-B1D1-21820C72912F Q38559336-1E3EE8FB-BB0E-454B-A661-B734366EB9AC Q38705627-DCF40682-1D65-4CB8-9620-926C2708417A Q38716573-E85FB48E-4BFA-46CA-84E5-440593A59582 Q38774730-E26DA8D4-9B3E-4A28-8C51-544B438F89AC Q38808957-99CDC936-29D1-42B7-B8EB-A5AA4A812791 Q38814327-274984AB-BA69-4192-A0DE-B57E9AB187E6 Q38831232-D35F4689-BF02-4B9C-805B-F8E72F727A8B Q38849192-2CD1FC0F-0945-45E4-833C-D76334C7B5A2 Q38928679-861630B7-20E0-4C1A-A6BC-8A26F63BFCB0 Q38982546-943DBDCD-43C4-4A23-A402-57FB60DE4B2E Q38999341-1D79A9EC-71ED-4326-8D72-4EFED4985D52 Q39077979-E2538722-0F33-411D-AD17-D99207BE2F59 Q40564594-CB294050-9B1F-4F5B-B244-22856CF9F659 Q41627655-AAA8A2F8-0AF8-42A6-AB70-02FBFD3A5987 Q41653596-2D7206EA-2BFB-49D9-A6A0-97AF0787D3C3 Q47106820-41977822-B323-49AB-982D-D605FF9CDC8D Q47744859-05EC2BA1-5DCB-4918-A038-1CB0EE0C2155 Q47916271-16F0E5CB-9F22-48B6-9E69-2214ED19F33E Q50475581-73355BF1-FF56-4D76-9751-79EBFDAEF08F Q52768383-0071179B-B0C2-4483-A19F-C8F8E68377D5 Q57442965-AB52150D-BE8F-4CC6-9F72-A5B5999C0466

P2860

PSMA-targeted theranostic nanoplex for prostate cancer therapy.

http://www.wikidata.org/entity/Q33791366

description

2012 nî lūn-bûn

@nan

2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

PSMA-targeted theranostic nanoplex for prostate cancer therapy.

@ast

PSMA-targeted theranostic nanoplex for prostate cancer therapy.

@en

type

label

PSMA-targeted theranostic nanoplex for prostate cancer therapy.

@ast

PSMA-targeted theranostic nanoplex for prostate cancer therapy.

@en

prefLabel

PSMA-targeted theranostic nanoplex for prostate cancer therapy.

@ast

PSMA-targeted theranostic nanoplex for prostate cancer therapy.

@en

P1433

Q33791366-CAF13C7A-A4BF-4171-9555-119E5688D13B

P1476

Q33791366-78593B78-C7EC-46D8-A928-40DAE1B3DF42

P2093

Q33791366-136BFE08-EA54-464B-9BD3-C259EF375B02

Q33791366-517AF18B-DDD0-4403-A329-28912F4D398C

Q33791366-5A1D9274-216D-4D58-B406-CF6CAF803A59

Q33791366-6B413E05-7C9C-4680-B323-FAD3C8A82034

Q33791366-79BB76E4-2BAD-49E4-9E92-9870B35EA436

Q33791366-AA267A56-0AEF-417F-8B4E-3CD398AC3848

Q33791366-C86843AB-4774-4E0D-B8A2-7E3730FED030

Q33791366-F2829DDF-3AA5-4B72-A5AF-529746A65C77

P2860

Q33791366-028BF8B6-4C7C-4370-8A7F-3B2F687DC852

Q33791366-036EBC57-1883-47D5-AD92-D41FA7A1C455

Q33791366-0448CC76-E876-4D84-AEC4-AE7F2DE2DB36

Q33791366-0541CC79-BAE5-4C8D-909B-826ACFAFCF36

Q33791366-0B39EA58-4691-4A15-BDDA-A65B337BE54D

Q33791366-0B9D524B-7AE0-4D9A-9776-BC0F813FDB8F

Q33791366-0BB70C99-5BF9-490E-952C-951CBB28949F

Q33791366-11ACBB80-AC8F-46B0-9300-5C870B249DC5

Q33791366-11DBAAB3-CDF0-448D-945A-B8B25D6BBA9B

Q33791366-1F213E4B-4BFA-4AFE-8619-E188ECDCE3D3

P304

Q33791366-FEF26FAE-9B4E-4EC6-86D1-9841DDAADA32

P31

Q33791366-68A12AB7-34D3-4DC5-8008-E77BA5F17676

P356

Q33791366-16D9BC87-2392-42D3-A1B9-EB6B2B16B4DD

P407

Q33791366-AEE69F05-152E-4271-8EBB-02680D034BB5

P433

Q33791366-B5F7B8FC-DCBC-4357-8B66-FD94FFD192A7

P478

Q33791366-BCBBF91A-965B-47E2-8449-FEA4E08F8AF5

P50

Q33791366-77CE42A1-2982-40FF-8659-D26FAF627E58

Q33791366-A0ECC3B3-A8F6-4053-AA29-2FAB11514A57

P577

Q33791366-1BD492B5-36BB-482E-8005-9AE327900710

P698

Q33791366-71CFD2C1-779A-4666-B6ED-4005C012527B

P932

Q33791366-0680A755-F302-48CD-82AC-BF6F49E44EA5

P356

P1433

P1476

PSMA-targeted theranostic nanoplex for prostate cancer therapy

@en

P2093

Cong Li

http://www.w3.org/2001/XMLSchema#string

Dmitri Artemov

http://www.w3.org/2001/XMLSchema#string

Kristine Glunde

http://www.w3.org/2001/XMLSchema#string

Marie-France Penet

http://www.w3.org/2001/XMLSchema#string

Martin G Pomper

http://www.w3.org/2001/XMLSchema#string

Paul T Winnard

http://www.w3.org/2001/XMLSchema#string

Sangeeta R Banerjee

http://www.w3.org/2001/XMLSchema#string

Zaver M Bhujwalla

http://www.w3.org/2001/XMLSchema#string

P2860

Choline Kinase: An Important Target for Cancer

Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans

Side-effects of a systemic injection of linear polyethylenimine-DNA complexes

5-fluorouracil: mechanisms of action and clinical strategies

Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II (NAALADase)

Choline kinase down-regulation increases the effect of 5-fluorouracil in breast cancer cells

Mechanisms of gene silencing by double-stranded RNA

Prostate-specific membrane antigen expression as a predictor of prostate cancer progression

Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine

P304

7752-7762

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/NN301725W

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Sridhar Nimmagadda

P577

2012-08-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22866897

http://www.w3.org/2001/XMLSchema#string

P932

4066818

http://www.w3.org/2001/XMLSchema#string